Selecta Biosciences, Inc.

NASDAQ
RNAC
Stock
Yield per half year: -51.73%
Dividend yield: 0%
Sector: Healthcare

9.09 $

0 $ 0%
8.77 $
36.58 $

Min/max per year

Share chart Selecta Biosciences, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Selecta Biosciences, Inc.

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia.

more details
It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Main settings

IPO date
2016-06-22
ISIN
US8162121045
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
link
All parameters

Grade

Underestimation
Title Value Grade
P/S 7.95 1
P/BV -45.49 0
P/E 0 0
Efficiency
Title Value Grade
ROA -20.92 0
ROE 34.64 9
ROIC 0 0
Dividends
Title Value Grade
Dividend yield 0 0
DSI 0 0
Average dividend growth 0 0
Debt
Title Value Grade
Debt/EBITDA -0.1813 10
Debt/Ratio 0.0321 10
Debt/Equity -64.96 10
Growth impulse
Title Value Grade
Yield Revenue, % 134.42 10
Yield Ebitda, % 36.04 5
Yield EPS, % 603.18 10
More

Prices

Price Min. Max. Change Changes in the industry Changes in the index
Yesterday 9.09 $ 0 $ 0 $ 0 % 0 % 0 %
Week 9.15 $ 0 $ 0 $ -0.6 % 0 % 0 %
Month 11.9 $ 8.77 $ 10.44 $ -23.61 % 0 % 0 %
Three month 18.01 $ 8.77 $ 18.06 $ -49.53 % 0 % 0 %
Half a year 18.83 $ 8.77 $ 24.43 $ -51.73 % 0 % 0 %
Year 31.44 $ 8.77 $ 36.58 $ -71.09 % 0 % 0 %
3 years 1.38 $ 0.5353 $ 36.58 $ 558.12 % 0 % 0 %
5 years 5.4 $ 0.5353 $ 36.58 $ 68.33 % 0 % 0 %
10 years 0 $ 0.5353 $ 52.66 $ 0 % 0 % 0 %
Year to date 18.47 $ 8.77 $ 19.99 $ -50.79 % 0 % 0 %

Main owners

Similar companies

P/E & P/BVEV/Ebitda & Debt/Ebitda


Company management

Head Job title Payment Year of birth
Dr. Carsten Brunn Ph.D. President, CEO & Director 4.67M 1971 (54 years)
Mr. Blaine T. Davis Chief Financial Officer 2.49M 1974 (51 year)
Mr. Matthew Bartholomae J.D. General Counsel & Secretary N/A
Dr. Metin Kurtoglu M.D., Ph.D. Chief Technology Officer 398.28k 1979 (46 years)
Dr. Chris Jewell Ph.D. Chief Scientific Officer 296.85k 1982 (43 years)
Dr. Milos Miljkovic M.D., Ph.D. Chief Medical Officer N/A 1984 (41 year)
Dr. Emily English Ph.D. SVP & Head of Manufacturing N/A 1980 (45 years)
Mr. Yi Zhang Ph.D. Senior Director of Technology N/A

About company

Address: United States, Watertown. MA, 65 Grove Street - Open in google maps, Open in yandex maps
Website: https://selectabio.com